Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Tikun Olam-Cannbit Pharmaceuticals Ltd
  6. News
  7. Summary
    TKUN   IL0010843675

TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD

(TKUN)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Tikun Olam-Cannbit Continues to Expand Its Footprint in the Pharmaceutical Arena

08/16/2021 | 07:00am EST

Tikun-Olam Cannbit reported the first and exclusive partnership of its kind with Wavelength, an Israeli company that develops, manufactures, and exports active pharmaceutical ingredients (APIs) for the pharmaceutical industry, to over 280 pharmaceutical companies in 50 different countries. Wavelength is a portfolio company of SK Capital Partners, a US-based investment firm with over $5 billion in assets under management, including 125 plants in 28 countries. Under the agreement, Tikun Olam-Cannbit and Wavelength will jointly develop, manufacture and market APIs, or in other words, active cannabis-based raw materials for the pharmaceutical industry.


ę S&P Capital IQ 2021
All news about TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
2021Teva Israel and Tikun Olam-Cannbit Pharmaceuticals Ltd Signs Mutual Collaboration Agree..
CI
2021Tikun Olam-Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended..
CI
2021Tikun Olam-Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 12 mill..
CI
2021Tikun Olam-Cannbit Continues to Expand Its Footprint in the Pharmaceutical Arena
CI
2021Tikun Olam - Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Full Year End..
CI
2021Canonic of Evogene Group and Tikun Olam-Cannbit, Sign Production and Distribution Agree..
CI
2021Tikun Olam-Cannabit and Opiostop LLC Are Establishing A JV to Conduct A Clinical Study ..
CI
2021Tikun Olam-Cannbit Develops Revolutionary System for the Characterization of Genetic Fi..
CI
2020Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 11.528 million in ..
CI
2019Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 10.0344 million in..
CI
More news
Financials
Sales 2020 21,7  6,93  6,93 
Net income 2020 -32,9 M -10,5 M -10,5 M
Net Debt 2020 5,33 M 1,71 M 1,71 M
P/E ratio 2020 -5,03x
Yield 2020 -
Capitalization 206 M 65,7 M 66,0 M
EV / Sales 2019 -
EV / Sales 2020 8 863 230x
Nbr of Employees 100
Free-Float 72,9%
Chart TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
Duration : Period :
Tikun Olam-Cannbit Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Ifat Kariv Chief Executive Officer & Director
Eitan Ben-Eliahu Chairman
Ronen Harel Independent External Director
Revital Aviram External Director
Orit Noked Independent Director